Keystone Investors PTE Ltd. Invests $2.31 Million in Protagonist Therapeutics, Inc. $PTGX

Keystone Investors PTE Ltd. acquired a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 26,390 shares of the company’s stock, valued at approximately $2,305,000.

A number of other large investors also recently modified their holdings of PTGX. Vanguard Group Inc. raised its holdings in shares of Protagonist Therapeutics by 27.2% in the 4th quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company’s stock worth $472,832,000 after purchasing an additional 1,156,461 shares during the period. Marshall Wace LLP purchased a new position in shares of Protagonist Therapeutics in the 3rd quarter worth about $72,114,000. Commodore Capital LP purchased a new position in shares of Protagonist Therapeutics in the 2nd quarter worth about $59,415,000. UBS Group AG raised its holdings in shares of Protagonist Therapeutics by 46.1% in the 4th quarter. UBS Group AG now owns 2,770,021 shares of the company’s stock worth $241,934,000 after purchasing an additional 874,013 shares during the period. Finally, Wellington Management Group LLP raised its holdings in shares of Protagonist Therapeutics by 83.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,908,446 shares of the company’s stock worth $126,778,000 after purchasing an additional 870,708 shares during the period. 98.63% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Protagonist Therapeutics news, CFO Asif Ali sold 1,750 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $105.47, for a total transaction of $184,572.50. Following the completion of the sale, the chief financial officer owned 59,003 shares in the company, valued at $6,223,046.41. This trade represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director William D. Waddill sold 9,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $107.68, for a total value of $969,120.00. Following the sale, the director owned 7,825 shares of the company’s stock, valued at approximately $842,596. This trade represents a 53.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 272,345 shares of company stock worth $27,676,386 over the last quarter. Corporate insiders own 5.19% of the company’s stock.

Protagonist Therapeutics Stock Performance

PTGX stock opened at $109.78 on Friday. Protagonist Therapeutics, Inc. has a 1 year low of $49.38 and a 1 year high of $111.78. The firm has a market cap of $7.06 billion, a P/E ratio of -60.65 and a beta of 1.85. The stock has a 50-day simple moving average of $101.71 and a 200-day simple moving average of $93.22.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.55. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%.The business had revenue of $56.37 million during the quarter, compared to analyst estimates of $11.70 million. On average, equities research analysts predict that Protagonist Therapeutics, Inc. will post 2.93 EPS for the current year.

Analyst Ratings Changes

PTGX has been the topic of a number of research reports. TD Cowen raised their price objective on Protagonist Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Truist Financial raised their price objective on Protagonist Therapeutics from $110.00 to $121.00 and gave the stock a “buy” rating in a report on Tuesday, April 14th. Barclays increased their target price on Protagonist Therapeutics from $113.00 to $119.00 and gave the company an “overweight” rating in a research note on Thursday, March 19th. Jefferies Financial Group reiterated a “buy” rating and issued a $121.00 target price on shares of Protagonist Therapeutics in a research note on Wednesday, March 18th. Finally, Wall Street Zen upgraded Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $115.21.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.